- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Impact of Glimepiride and Metformin on the Biomarker miR-150-5p in Patients with Type 2 Diabetes and Left Ventricular Diastolic Dysfunction | ||
| Annals of the College of Medicine, Mosul | ||
| Volume 46, Issue 2, December 2024, Pages 224-234 PDF (730.69 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.33899/mmed.2024.150823.1272 | ||
| Authors | ||
| zahraa Razaq Mohammed* 1; Hussein Ali Saheb2 | ||
| 1College of Medicine, University of Al-Qadisiyah | ||
| 2College of Pharmacy, University of Al-Qadisiyah | ||
| Abstract | ||
| Background: Type-2 diabetes mellitus (T2DM) is a significant contributor to cardiovascular risk, with diabetic individuals having double the mortality rate compared to those without diabetes. Among the various early subclinical cardiac problems in type 2 diabetes, left ventricular diastolic dysfunction (LVDD) is the most easily identifiable impairment. Nevertheless, only a limited number of biomarkers can accurately forecast this group's cardiovascular events. Levels of miR-150-5p are reduced in patients with type 2 diabetes mellitus (T2DM), regardless of whether they have cardiovascular disease. Our findings also demonstrate a decrease in miR-150-5p levels in these patients. Lower levels of miR-150-5p in the blood have been observed in nearly all forms of cardiovascular disease, and its potential to predict various clinical outcomes has been extensively studied in patients. Objective: To assess the effect of glimepride (Glm) and Metformin on cardiac parameter miR-150-5p in patients with type 2 diabetes and diastolic dysfunction. Patients and methods: In a cross-sectional study that included 60 patients with type 2 diabetes and diastolic dysfunction in an age range of 45 to 65, the patients were divided into two groups: group G1 (received standard treatment for T2DM with Metformin 1g×2 max daily dose ) and group G2 (received standard treatment for T2DM with Metformin + Glimepiride 4mg daily). Results: Treatment with glimepride significantly increased miR-150-5p expression in patients with type 2 diabetes mellitus (T2DM) and left ventricular diastolic dysfunction (LVDD), according to this study. The rise was more pronounced in patients who were given Glimepiride and standard medical treatment. Conclusions: Glimepiride plays an important role in improving cardiac biomarkers like miR-150-5p. Glimepiride use in diabetic patients with the addition of Metformin to usual diabetes type 2 treatment may benefit patients with cardiac complications. | ||
| Keywords | ||
| :Glimepride; Metformin; left ventricular diastolic dysfunction; type 2 diabetes mellitus; miR-150-5p | ||
|
Statistics Article View: 214 PDF Download: 56 |
||